Table 3.
Adherence to CVD Drugs During Follow-up by Study Arm*†
| KP sites | All sites | |||||
|---|---|---|---|---|---|---|
| Drug class | Intervention, % (95% CI) | Control, % (95% CI) | p value | Intervention, % (95% CI) | Control, % (95% CI) | p value |
| Metformin | 51.5% (50.2, 52.8) | 49.5% (48.2, 50.7) | 0.03 | 55.0% (5,3.8 56.1) | 53.6% (52.4, 54.7) | 0.09 |
| Sulfonylureas | 51.1% (49.6, 52.6) | 51.4% (49.9, 52.8) | 0.83 | 52.7% (51.2, 54.1) | 52.8% (51.4, 54.2) | 0.90 |
| Statins | 55.0% (53.8, 56.1) | 55.5% (54.4, 56.6) | 0.50 | 54% (53.0, 55.1) | 54% (53.3, 55.4) | 0.62 |
| Ace inhibitors | 57.7% (56.0, 59.4) | 56.4% (54.8, 58.1) | 0.31 | 56.7% (55.1, 58.3) | 56.2% (54.6, 57.7) | 0.63 |
| Beta blockers | 54.9% (52.8, 56.9) | 53.4% (51.4,55.3) | 0.30 | 55.9% (54.0, 57.7) | 54.5% (52.7, 56.4) | 0.31 |
| Calcium channel blockers | 59.4% (56.8,62.0) | 59.0% (56.4, 61.6) | 0.83 | 59.5% (57.1, 61.9) | 58.0% (55.6, 60.4) | 0.38 |
| ARBs | 63.8% (61.5, 66.0) | 61.8% (59.5, 64.0) | 0.23 | 62.3% (60.2, 64.5) | 61.0% (58.9, 63.2) | 0.40 |
| Diuretics | 57.0% (55.0, 59.0) | 57.3% (55.4, 59.3) | 0.81 | 57.1% (55.3, 58.9) | 56.5% (54.7, 58.3) | 0.65 |
*Denominator restricted to those who were non-adherent at baseline and had at least 2 metformin fills during follow-up (KP sites = 12,062; all sites = 14,368)
†Table includes the most commonly used drugs, with the power to detect differences